Amneal Pharmaceuticals, Inc.
AMRX
$10.48
$0.121.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 101.93% | 92.27% | -39.16% | -1,886.83% | -8,426.17% |
| Total Depreciation and Amortization | 8.93% | 6.19% | 2.96% | -2.80% | -5.33% |
| Total Amortization of Deferred Charges | 95.34% | 158.61% | 264.81% | 126.44% | 143.72% |
| Total Other Non-Cash Items | -40.23% | -43.67% | -41.59% | 30.90% | 53.81% |
| Change in Net Operating Assets | -54.57% | 13.19% | 91.38% | 111.77% | 74.59% |
| Cash from Operations | 39.06% | 52.35% | -14.61% | 67.78% | 27.09% |
| Capital Expenditure | -78.10% | -41.66% | -28.93% | -6.87% | 12.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 40.41% | -- | -- | -- | -- |
| Other Investing Activities | 70.33% | 71.18% | 34.56% | -1,264.55% | 5.82% |
| Cash from Investing | -13.62% | 20.95% | 8.95% | -60.59% | 15.83% |
| Total Debt Issued | -43.34% | -46.14% | -89.01% | 240.67% | 284.73% |
| Total Debt Repaid | 5.53% | -0.12% | 43.70% | -160.19% | -182.01% |
| Issuance of Common Stock | 81.84% | 149.48% | 155.88% | 156.37% | 97.87% |
| Repurchase of Common Stock | -190.42% | -195.71% | -234.40% | -234.24% | -233.59% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 81.76% | 91.03% | 91.48% | -146.18% | -372.42% |
| Cash from Financing | 4.58% | -2.23% | 0.37% | -87.76% | -162.86% |
| Foreign Exchange rate Adjustments | -312.57% | -50.40% | -1,636.92% | 98.50% | 90.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 152.42% | 116.87% | -69.77% | -5,978.17% | -496.10% |